Recce Pharmaceuticals (ASX:RCE) said phase two clinical trials of its topical gel Recce 327 (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) showed that the gel is safe and well-tolerated with no serious adverse effects on patients, according to a Monday filing with the Australian bourse.
After 14 days of treatment, 27 out of 29 patients treated with R327G achieved the primary efficacy endpoint, the filing said.
The study's assessments observed wound healing, with the potential for full recovery after 14 days, the filing added.
Based on the trial's results, experts believe the company's registrational phase 3 study for diabetic foot infections can achieve a statistically "significant" positive endpoint after enrolling around 100 patients, the filing added.
Shares of the company rose past 2% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。